# Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

> **NCT00005906** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 4 (actual)

## Conditions studied

- Lymphangioleiomyomatosis
- Lymphangiomyomas
- Pleural Effusions
- Ascites

## Interventions

- **DRUG:** Octreotide

## Key facts

- **NCT ID:** NCT00005906
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2008-04
- **Final completion:** —
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2010-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005906, "Treatment With Octreotide in Patients With Lymphangioleiomyomatosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00005906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*